7210 Wareham Drive, Tampa, FL 33647
Nov. 6, 2025 Weight loss products are a major part of Herbalife’s business, accounting for 55% of total sales for the first nine months of 2025. According to Stephan Gratziani, CEO,… “Herbalife’s third-quarter performance reflects continued progress in our transformation strategy, as well as disciplined financial and operational execution. With North America returning to growth […]
Herbalife Reports 3rd Qtr. Results Read More »
Nov. 6, 2025 According to WW management: “WeightWatchers is entering a new era, uniquely positioned at the intersection of medical innovation and behavioral science, to lead this rapidly evolving weight health market,” said Tara Comonte, CEO of WeightWatchers. “GLP-1s are a breakthrough in obesity care, but real success, with or without medication, comes from combining
Weight Watchers Reports 3rd Qtr. Results Read More »
April 30, 2025 Herbalife today reported its first quarter 2025 results. The company sells a significant amount of weight management products (meal replacements), and is one the the leading MLM companies selling weight loss products. At $254.4 million, North American sales represented 20.8% of total Herbalife revenues for the quarter. The company had worldwide weight
Herbalife Reports Q1 2025 Results Read More »
April 29, 2025 WW announced a pharmacy integration with Eli Lilly and Company’s LillyDirect® pharmacy provider, Gifthealth. The integration will streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers Clinic members with an on-label prescription from their clinician. As part of WeightWatchers’ holistic approach to weight management, the integration will streamline access to
Weight Watchers Streamlines Member Access to Zepbound® Vials Read More »
April 24, 2025 Novo Nordisk asked the Food and Drug Administration to approve a pill version of its popular weight loss drug in obesity earlier this year, a spokesperson confirmed. The company first reported in 2023 that the drug, an oral form of semaglutide, succeeded in a Phase 3 trial, helping people on the highest
Novo Nordisk Submits Weight Loss Pill for FDA Approval Read More »
April 22, 2025 Marketdata LLC has just released a new market study: “The U.S. Meal Replacements Market: Retail & MLM Channels”, April 2025. This 77-page report analyses the meal replacements and retail appetite suppressants market in the U.S. The $5.1 billion U.S. meal replacements market has held up fairly well the past few years, despite
$5 Billion U.S. Meal Replacements Market Survives GLP-1s Competition Read More »
April 9, 2025 (Reuters) – WW International may be preparing to file for bankruptcy in the coming months as part of a plan to hand control of the business to its creditors, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Shares of the company tumbled nearly 59% to 18 cents
Weight Watchers Prepares for Possible Bankruptcy Filing Read More »
March 24, 2025 Marketdata LLC has just published a new report: “The U.S. Weight Loss Market: Commercial (non-medical) Programs & Products”, March 2025. This is a 220-page analysis of commercial weight loss programs/companies and how they have been affected by and respond to the onslaught of the GLP-1 drugs competition. The $38 billion U.S. commercial weight loss
$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion Read More »
March 14, 2025 On Mar. 5, a judge denied a request from the Outsourcing Facilities Association (OFA), an industry group for compounding pharmacies, to block the FDA’s attempt to stop the production of compounded tirzepatide. Generally, making copies of brand-name drugs is not legal until their patents expire. But there are exceptions: Compounding pharmacies can
FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down Read More »
March 13, 2025 Marketdata, the parent company of DietBusinessWatch.com, has updated its report on the Commercial & Retail Weight Loss Market. Several things have become apparent as we do the research Marketdata analysts see a possible opportunity this year for the commercial (non-medical) weight loss firms to recover some ground. Here’s how we think 2025
Recession Is Coming – But Commercial Diet Companies Could Benefit Read More »